| A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures KH Dinnon III, SR Leist, A Schäfer, CE Edwards, DR Martinez, ... Nature 586 (7830), 560-566, 2020 | 647 | 2020 |
| Identification of a prenylation site in delta virus large antigen JS Glenn, JA Watson, CM Havel, JM White Science 256 (5061), 1331-1333, 1992 | 405 | 1992 |
| Structural linkage between ligand discrimination and receptor activation by type I interferons C Thomas, I Moraga, D Levin, PO Krutzik, Y Podoplelova, A Trejo, C Lee, ... Cell 146 (4), 621-632, 2011 | 377 | 2011 |
| Progenitor identification and SARS-CoV-2 infection in human distal lung organoids AA Salahudeen, SS Choi, A Rustagi, J Zhu, V van Unen, SM de la O, ... Nature 588 (7839), 670-675, 2020 | 329 | 2020 |
| Six RNA viruses and forty-one hosts: viral small RNAs and modulation of small RNA repertoires in vertebrate and invertebrate systems P Parameswaran, E Sklan, C Wilkins, T Burgon, MA Samuel, R Lu, ... PLoS pathogens 6 (2), e1000764, 2010 | 299 | 2010 |
| Structure of the neurotensin receptor 1 in complex with β-arrestin 1 W Huang, M Masureel, Q Qu, J Janetzko, A Inoue, HE Kato, MJ Robertson, ... Nature 579 (7798), 303-308, 2020 | 289 | 2020 |
| Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis S Einav, D Gerber, PD Bryson, EH Sklan, M Elazar, SJ Maerkl, JS Glenn, ... Nature biotechnology 26 (9), 1019, 2008 | 288 | 2008 |
| Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial C Koh, L Canini, H Dahari, X Zhao, SL Uprichard, V Haynes-Williams, ... The Lancet Infectious Diseases 15 (10), 1167-1174, 2015 | 285 | 2015 |
| An N-terminal amphipathic helix in hepatitis C virus (HCV) NS4B mediates membrane association, correct localization of replication complex proteins, and HCV RNA replication M Elazar, P Liu, CM Rice, JS Glenn Journal of virology 78 (20), 11393-11400, 2004 | 261 | 2004 |
| RNA genome conservation and secondary structure in SARS-CoV-2 and SARS-related viruses: a first look R Rangan, IN Zheludev, RJ Hagey, EA Pham, HK Wayment-Steele, ... Rna 26 (8), 937-959, 2020 | 252 | 2020 |
| In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus BB Bordier, J Ohkanda, P Liu, SY Lee, FH Salazar, PL Marion, K Ohashi, ... The Journal of clinical investigation 112 (3), 407-414, 2003 | 252 | 2003 |
| Amphipathic helix-dependent localization of NS5A mediates hepatitis C virus RNA replication M Elazar, KH Cheong, P Liu, HB Greenberg, CM Rice, JS Glenn Journal of virology 77 (10), 6055-6061, 2003 | 247 | 2003 |
| Sustained survival of human hepatocytes in mice: a model for in vivo infection with human hepatitis B and hepatitis delta viruses K Ohashi, PL Marion, H Nakai, L Meuse, JM Cullen, BB Bordier, ... Nature medicine 6 (3), 327-331, 2000 | 227 | 2000 |
| COVID-19 and emerging viral infections: The case for interferon lambda L Prokunina-Olsson, N Alphonse, RE Dickenson, JE Durbin, JS Glenn, ... Journal of Experimental Medicine 217 (5), 2020 | 220 | 2020 |
| Changing trends in etiology-based annual mortality from chronic liver disease, from 2007 through 2016 D Kim, AA Li, C Gadiparthi, MA Khan, G Cholankeril, JS Glenn, A Ahmed Gastroenterology 155 (4), 1154-1163. e3, 2018 | 213 | 2018 |
| Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial JJ Feld, C Kandel, MJ Biondi, RA Kozak, MA Zahoor, C Lemieux, ... The Lancet Respiratory Medicine 9 (5), 498-510, 2021 | 204 | 2021 |
| A nucleotide binding motif in hepatitis C virus (HCV) NS4B mediates HCV RNA replication S Einav, M Elazar, T Danieli, JS Glenn Journal of virology 78 (20), 11288-11295, 2004 | 199 | 2004 |
| Extracellular cGAMP is a cancer-cell-produced immunotransmitter involved in radiation-induced anticancer immunity JA Carozza, V Böhnert, KC Nguyen, G Skariah, KE Shaw, JA Brown, ... Nature Cancer 1 (2), 184-196, 2020 | 196 | 2020 |
| Changing trends in etiology‐based and ethnicity‐based annual mortality rates of cirrhosis and hepatocellular carcinoma in the United States D Kim, AA Li, BJ Perumpail, C Gadiparthi, W Kim, G Cholankeril, JS Glenn, ... Hepatology 69 (3), 1064-1074, 2019 | 180 | 2019 |
| Parallel shRNA and CRISPR-Cas9 screens enable antiviral drug target identification RM Deans, DW Morgens, A Ökesli, S Pillay, MA Horlbeck, M Kampmann, ... Nature chemical biology 12 (5), 361-366, 2016 | 174 | 2016 |
